TB prevention study halted early – only 16 volunteers enrolled

NCT ID NCT04453293

Terminated Prevention Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a single dose of the BCG vaccine could prevent tuberculosis infection in healthy adults traveling to countries with high TB rates. Participants were randomly assigned to receive either BCG or a placebo. The study was terminated early and enrolled only 16 out of a planned 2000 volunteers, so no reliable conclusions can be drawn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS INFECTION

Contacts and locations

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
Hope Clinic of the Emory University Vaccine Center, Emory University

Decatur, Georgia, 30030, United States
Johns Hopkins Bloomberg School of Public Health, Department of International Health, Center for Immunization Research

Baltimore, Maryland, 21205, United States
MedStar Washington Hospital Center/MedStar Health Research Institute

Washington D.C., District of Columbia, 20010, United States
The Brigham and Women's Hospital Center for Clinical Investigation

Boston, Massachusetts, 02115, United States
University of Utah School of Medicine

Salt Lake City, Utah, 84108, United States
Yale University School of Medicine

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.